Insider trade

Janux Therapeutics (JANX): Director bought ~$3.42M

RA CAPITAL MANAGEMENT, Director at Janux Therapeutics, bought ~$3.42M of Janux Therapeutics shares.

~$3.42M
Approx. value · 110K sh @ $31.02
10.1M
Holds after · shares reported
Traded
Mar 7, 2025
Filed
Mar 7, 2025

What stands out in this filing

  • After this purchase the filing reports 10,141,287 shares, held indirectly.
  • 110,206 shares at an average of $31.02 each, as reported on the form.
  • The first open-market purchase by this insider in 0 months.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 7, 2025InsiderCEO sold ~$300K of JANX shares in the open market
  2. Feb 3, 2025Insider · 1 personInsiders: 3 sales (~$141K)
  3. Mar 3, 2025Insider · 1 personInsiders: 2 sales (~$107K)
  4. Mar 5, 2025Insider · 1 personInsiders: 2 purchases (~$10.5M)
  5. Mar 6, 2025InsiderDirector purchased ~$11.5M of JANX shares in the open market
  6. Mar 7, 2025 · this disclosureInsiderDirector purchased ~$3.42M of JANX shares in the open market

What came next

  1. Apr 21, 2025InsiderOfficer sold ~$100K of JANX shares in the open market
  2. May 1, 2025Insider · 1 personInsiders: 2 sales (~$107K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Janux Therapeutics

OQRO holds no insider, Congress, fund or contract record for Janux Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JANX page.

Other recent filings by RA CAPITAL MANAGEMENT, L.P., Director

The full history of RA CAPITAL MANAGEMENT, L.P., Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Janux Therapeutics (JANX) insider traded, and how much?

RA CAPITAL MANAGEMENT, Director at Janux Therapeutics, bought ~$3.42M of Janux Therapeutics shares. 110K shares at $31.02, open market.

When did it happen, and when was it made public?

Traded: Mar 7, 2025. Filed: Mar 7, 2025.

What stands out in this filing?

After this purchase the filing reports 10,141,287 shares, held indirectly. 110,206 shares at an average of $31.02 each, as reported on the form. The first open-market purchase by this insider in 0 months.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean JANX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Janux Therapeutics

Everything OQRO holds on this company is on its JANX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data